1113 related articles for article (PubMed ID: 28524659)
41. Molecular docking and dynamics studies of 4-anilino quinazolines for epidermal growth factor receptor tyrosine kinase to find potent inhibitor.
Muthuvel SK; Elumalai E; K G; K H
J Recept Signal Transduct Res; 2018; 38(5-6):475-483. PubMed ID: 31038021
[TBL] [Abstract][Full Text] [Related]
42. Synthesis, Biological Activities and Docking Studies of Novel 4-(Arylaminomethyl)benzamide Derivatives as Potential Tyrosine Kinase Inhibitors.
Kalinichenko E; Faryna A; Kondrateva V; Vlasova A; Shevchenko V; Melnik A; Avdoshko O; Belko A
Molecules; 2019 Sep; 24(19):. PubMed ID: 31574962
[TBL] [Abstract][Full Text] [Related]
43. Synthesis and biological evaluation of novel aromatic-heterocyclic biphenyls as potent anti-leukemia agents.
Dong J; Pan X; Wang J; Su P; Zhang L; Wei F; Zhang J
Eur J Med Chem; 2015 Aug; 101():780-9. PubMed ID: 26231079
[TBL] [Abstract][Full Text] [Related]
44. The Performance of Several Docking Programs at Reproducing Protein-Macrolide-Like Crystal Structures.
Castro-Alvarez A; Costa AM; Vilarrasa J
Molecules; 2017 Jan; 22(1):. PubMed ID: 28106755
[TBL] [Abstract][Full Text] [Related]
45. Novel 3-(2-(3-methyl-5-substituted-phenyl-4,5-dihydropyrazol-1-yl)-2-oxoethoxy)-2-substituted-phenyl-4H-chromen-4-one: synthesis and anticancer activity.
Liu XH; Li J; Wu FR; Song BA; Bhadury PS; Shi L
Med Chem; 2011 Nov; 7(6):605-10. PubMed ID: 22313300
[TBL] [Abstract][Full Text] [Related]
46. Binding mode analysis, dynamic simulation and binding free energy calculations of the MurF ligase from Acinetobacter baumannii.
Ahmad S; Raza S; Uddin R; Azam SS
J Mol Graph Model; 2017 Oct; 77():72-85. PubMed ID: 28843462
[TBL] [Abstract][Full Text] [Related]
47. Searching for Potential Novel BCR-ABL Tyrosine Kinase Inhibitors Through G-QSAR and Docking Studies of Some Novel 2-Phenazinamine Derivatives.
Kale M; Sonwane G; Choudhari Y
Curr Comput Aided Drug Des; 2020; 16(5):501-510. PubMed ID: 30345925
[TBL] [Abstract][Full Text] [Related]
48. Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors.
Zhu W; Chen C; Sun C; Xu S; Wu C; Lei F; Xia H; Tu Q; Zheng P
Eur J Med Chem; 2015 Mar; 93():64-73. PubMed ID: 25659752
[TBL] [Abstract][Full Text] [Related]
49. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
50. Anticancer properties of N-alkyl-2, 4-diphenylimidazo [1, 2-a] quinoxalin-1-amine derivatives; kinase inhibitors.
Rezaei Z; Mahdi Didehvar M; Mahdavi M; Azizian H; Hamedifar H; Mohammed EHM; Ostad S; Amini M
Bioorg Chem; 2019 Sep; 90():103055. PubMed ID: 31220669
[TBL] [Abstract][Full Text] [Related]
51. Design, synthesis, and biological activity of 4-(imidazo[1,2-b]pyridazin-3-yl)-1H-pyrazol-1-yl-phenylbenzamide derivatives as BCR-ABL kinase inhibitors.
Hu L; Cao T; Lv Y; Ding Y; Yang L; Zhang Q; Guo M
Bioorg Med Chem Lett; 2016 Dec; 26(23):5830-5835. PubMed ID: 28029512
[TBL] [Abstract][Full Text] [Related]
52. Chemical Characterization,
Ansari JA; Ahmad MK; Fatima N; Azad I; Mahdi AA; Satyanarayan GNV; Ahmad N
Anticancer Agents Med Chem; 2022; 22(20):3416-3437. PubMed ID: 35125087
[TBL] [Abstract][Full Text] [Related]
53. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
54. Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: Structure-based virtual screening, molecular docking and dynamics simulation studies.
Uba AI; Yelekçi K
Comput Biol Chem; 2018 Aug; 75():131-142. PubMed ID: 29859380
[TBL] [Abstract][Full Text] [Related]
55. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
56. Chromones bearing amino acid residues: Easily accessible and potent inhibitors of the breast cancer resistance protein ABCG2.
Roussel E; Moréno A; Altounian N; Philouze C; Pérès B; Thomas A; Renaudet O; Falson P; Boumendjel A
Eur J Med Chem; 2020 Sep; 202():112503. PubMed ID: 32653696
[TBL] [Abstract][Full Text] [Related]
57. Dexibuprofen amide derivatives as potential anticancer agents: synthesis, in silico docking, bioevaluation, and molecular dynamic simulation.
Ashraf Z; Mahmood T; Hassan M; Afzal S; Rafique H; Afzal K; Latip J
Drug Des Devel Ther; 2019; 13():1643-1657. PubMed ID: 31190743
[TBL] [Abstract][Full Text] [Related]
58. Synthesis, Antitumor Activity and Molecular Docking Studies on Seven Novel Thiazacridine Derivatives.
Almeida ML; Viana DCF; da Costa VCM; Dos Santos FA; Pereira MC; Pitta MGR; de Melo Rêgo MJB; Pitta IR; Pitta MGR
Comb Chem High Throughput Screen; 2020; 23(5):359-368. PubMed ID: 32189590
[TBL] [Abstract][Full Text] [Related]
59. Design, synthesis, and biological evaluation of chromone-based p38 MAP kinase inhibitors.
Dyrager C; Möllers LN; Kjäll LK; Alao JP; Dinér P; Wallner FK; Sunnerhagen P; Grøtli M
J Med Chem; 2011 Oct; 54(20):7427-31. PubMed ID: 21905739
[TBL] [Abstract][Full Text] [Related]
60. Ligand-Based Drug Design: Synthesis and Biological Evaluation of Substituted Benzoin Derivatives as Potential Antitumor Agents.
Sabbah DA; Ibrahim AH; Talib WH; Alqaisi KM; Sweidan K; Bardaweel SK; Sheikha GA; Zhong HA; Al-Shalabi E; Khalaf RA; Mubarak MS
Med Chem; 2019; 15(4):417-429. PubMed ID: 30207238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
